Abstract：
Both the incidence and prevalence of well-differentiated neuroendocrine tumours from the small intestine (Si-NET) are gradually increasing. Most patients have non-functioning tumours with subtle GI symptoms and tumours are often discovered incidentally by endoscopy or at advanced disease stages by imaging depicting mesenteric lymph node and /or liver metastases while around 30% of the patients present with symptoms of the carcinoid syndrome. Adequate biochemical assessment and staging including functional imaging is crucial for treatment-related decision-making that should take place in an expert multidisciplinary team setting. Preferably, patients should be referred to specialised ENETS Centres of Excellence or centres of high expertise in the field. This guidance paper provides the current evidence and best knowledge for the management of Si-NET grade (G) 1-3 following 10 key questions of practical relevance for the diagnostic and therapeutic decision making.
摘要：
来自小肠的分化良好的神经内分泌肿瘤（Si-NET）的发病率和患病率都在逐渐增加。大多数患者患有无功能的肿瘤，具有轻微的胃肠道症状，并且肿瘤通常是通过内窥镜检查偶然发现的，或者在疾病晚期通过描绘肠系膜淋巴结和/或肝转移的成像发现的，而大约30％的患者表现出类癌综合征的症状。充分的生化评估和分期，包括功能成像，对于治疗相关的决策至关重要，这应该在专家多学科团队环境中进行。最好,应将患者转介至专门的ENETS卓越中心或该领域的高专业知识中心。本指导文件为Si-NET等级（G）1-3的管理提供了当前的证据和最佳知识，这些问题与诊断和治疗决策具有实际相关性。
